[NSCLC and new oncogenic mutations: Diagnosis and perspectives].
Carcinome bronchique non à petites cellules : nouvelles addictions oncogéniques, diagnostic et perspectives.
Biologie moléculaire
Cancers bronchiques
Clinical trials
Essais cliniques
Lung cancer
Molecular biology
Stade IV
Stage IV
Targeted treatments
Traitement ciblés
Journal
Revue des maladies respiratoires
ISSN: 1776-2588
Titre abrégé: Rev Mal Respir
Pays: France
ID NLM: 8408032
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
17
11
2020
accepted:
09
02
2021
pubmed:
23
5
2021
medline:
18
9
2021
entrez:
22
5
2021
Statut:
ppublish
Résumé
The development of new targeted therapies in non-small cell lung carcinoma (NSCLC) depends on a better understanding of the molecular basis of carcinogenesis, a knowledge of the role of molecular aberrations in disease progression and the development of molecular biology platforms with the capacity to identify new biomarkers. In the current article, we review the techniques routinely used in cancer molecular biology platforms as well as new techniques under development. These new NSCLC biomarkers have been made available to clinicians and biologists in parallel with the development of targeted drugs. New molecular abnormalities of EGFR exon 20, HER2, MET, RET, BRAF, ROS1 and NTRK have been identified and there have been clinical trials of the most innovative targeted drugs.
Identifiants
pubmed: 34020835
pii: S0761-8425(21)00174-1
doi: 10.1016/j.rmr.2021.02.069
pii:
doi:
Substances chimiques
Proto-Oncogene Proteins
0
Protein-Tyrosine Kinases
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
477-488Informations de copyright
Copyright © 2021 SPLF. Published by Elsevier Masson SAS. All rights reserved.